The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma

Clinical Nutrition

Volumn 35, Issue 5, 2016, Pages 1103-1109

  Rollins, Katie E ^a   Tewari, Nilanjana ^a   Ackner, Abigail ^a   Awwad, Amir ^b   Madhusudan, Srinivasan ^c   Macdonald, Ian A ^b   Fearon, Kenneth C H ^d   Lobo, Dileep N ^a  

^a NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cholangiocarcinoma; Inflammation; Myosteatosis; Pancreatic cancer; Sarcopenia; Survival

Indexed keywords

C REACTIVE PROTEIN; GEMCITABINE; UREA; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BODY COMPOSITION; DISEASE ASSOCIATION; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; MYOSTEATOSIS; NEUTROPHIL LYMPHOCYTE RATIO; OBESITY; OVERALL SURVIVAL; PANCREAS CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SARCOPENIA; SKELETAL MUSCLE; UREA BLOOD LEVEL; BILE DUCT TUMOR; BODY MASS; COMPLICATION; METABOLISM; MIDDLE AGED; NEUTROPHIL; PANCREAS TUMOR; PATHOLOGY; PREVALENCE; PROGNOSIS; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLANGIOCARCINOMA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEUTROPHILS; OBESITY; PANCREATIC NEOPLASMS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOPENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84950119839     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2015.08.005     Document Type: Article

References (40)

1. [1] Vincent, A., Herman, J., Schulick, R., Hruban, R.H., Goggins, M., Pancreatic cancer. Lancet 378 (2011), 607–620.
2. [2] Neoptolemos, J.P., Stocken, D.D., Friess, H., Bassi, C., Dunn, J.A., Hickey, H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004), 1200–1210.
3. [3] Falconer, J.S., Fearon, K.C., Plester, C.E., Ross, J.A., Carter, D.C., Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219 (1994), 325–331.
4. [4] Wigmore, S.J., Plester, C.E., Richardson, R.A., Fearon, K.C., Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75 (1997), 106–109.
5. [5] Fearon, K.C., Voss, A.C., Hustead, D.S., Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83 (2006), 1345–1350.
6. [6] Ozola Zalite, I., Zykus, R., Francisco Gonzalez, M., Saygili, F., Pukitis, A., Gaujoux, S., et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology 15 (2015), 19–24.
7. [7] Bachmann, J., Heiligensetzer, M., Krakowski-Roosen, H., Buchler, M.W., Friess, H., Martignoni, M.E., Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 12 (2008), 1193–1201.
8. [8] Baracos, V.E., Reiman, T., Mourtzakis, M., Gioulbasanis, I., Antoun, S., Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 91 (2010), 1133S–1137S.
9. [9] Prado, C.M., Baracos, V.E., McCargar, L.J., Mourtzakis, M., Mulder, K.E., Reiman, T., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13 (2007), 3264–3268.
10. [10] Prado, C.M., Baracos, V.E., McCargar, L.J., Reiman, T., Mourtzakis, M., Tonkin, K., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15 (2009), 2920–2926.
11. [11] Prado, C.M., Lieffers, J.R., McCargar, L.J., Reiman, T., Sawyer, M.B., Martin, L., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9 (2008), 629–635.
12. [12] Tan, B.H., Birdsell, L.A., Martin, L., Baracos, V.E., Fearon, K.C., Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15 (2009), 6973–6979.
13. [13] Mitsiopoulos, N., Baumgartner, R.N., Heymsfield, S.B., Lyons, W., Gallagher, D., Ross, R., Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85 (1998), 115–122.
14. [14] Vehmas, T., Kairemo, K.J.A., Taavitsainen, M.J., Measuring visceral adipose tissue content from contrast enhanced computed tomography. Int J Obes 20 (1996), 570–573.
15. [15] Kvist, H., Sjostrom, L., Tylen, U., Adipose-tissue volume determinations in women by computed-tomography – technical considerations. Int J Obes 10 (1986), 53–67.
16. [16] Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metabol 33 (2008), 997–1006.
17. [17] Tsai, S., Importance of lean body mass in the oncologic patient. Nutr Clin Pract 27 (2012), 593–598.
18. [18] Awad, S., Tan, B.H., Cui, H., Bhalla, A., Fearon, K.C., Parsons, S.L., et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 31 (2012), 74–77.
19. [19] Dalal, S., Hui, D., Bidaut, L., Lem, K., Del Fabbro, E., Crane, C., et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage 44 (2012), 181–191.
20. [20] Miljkovic, I., Zmuda, J.M., Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care 13 (2010), 260–264.
21. [21] Aubrey, J., Esfandiari, N., Baracos, V.E., Buteau, F.A., Frenette, J., Putman, C.T., et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf) 210 (2014), 489–497.
22. [22] Goodpaster, B.H., Thaete, F.L., Kelley, D.E., Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci 904 (2000), 18–24.
23. [23] Lee, S., Kuk, J.L., Davidson, L.E., Hudson, R., Kilpatrick, K., Graham, T.E., et al. Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without type 2 diabetes. J Appl Physiol 99 (2005), 1220–1225.
24. [24] Anderson, D.E., D'Agostino, J.M., Bruno, A.G., Demissie, S., Kiel, D.P., Bouxsein, M.L., Variations of CT-based trunk muscle attenuation by age, sex, and specific muscle. J Gerontol A Biol Sci Med Sci 68 (2013), 317–323.
25. [25] Kalichman, L., Hodges, P., Li, L., Guermazi, A., Hunter, D.J., Changes in paraspinal muscles and their association with low back pain and spinal degeneration: CT study. Eur Spine J 19 (2010), 1136–1144.
26. [26] Kelley, D.E., McKolanis, T.M., Hegazi, R.A., Kuller, L.H., Kalhan, S.C., Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285 (2003), E906–E916.
27. [27] Taaffe, D.R., Henwood, T.R., Nalls, M.A., Walker, D.G., Lang, T.F., Harris, T.B., Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology 55 (2009), 217–223.
28. [28] Malietzis, G., Johns, N., Al-Hassi, H.O., Knight, S.C., Kennedy, R.H., Fearon, K.C., et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann Surg, 2015, 10.1097/SLA.0000000000001113 [Epub ahead of print], PMID: 25643288.
29. [29] Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31 (2013), 1539–1547.
30. [30] Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982), 649–655.
31. [31] Malietzis, G., Giacometti, M., Kennedy, R.H., Athanasiou, T., Aziz, O., Jenkins, J.T., The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol 21 (2014), 3938–3946.
32. [32] Ben, Q., An, W., Wang, L., Wang, W., Yu, L., Yuan, Y., Validation of the pretreatment neutrophil–lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Pancreas 44 (2015), 471–477.
33. [33] Martin, H.L., Ohara, K., Kiberu, A., Van Hagen, T., Davidson, A., Khattak, M.A., Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J 44 (2014), 676–682.
34. [34] Szkandera, J., Stotz, M., Absenger, G., Stojakovic, T., Samonigg, H., Kornprat, P., et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 110 (2014), 183–188.
35. [35] Di Sebastiano, K.M., Yang, L., Zbuk, K., Wong, R.K., Chow, T., Koff, D., et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br J Nutr 109 (2013), 302–312.
36. [36] House, M.G., Fong, Y., Arnaoutakis, D.J., Sharma, R., Winston, C.B., Protic, M., et al. Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg 12 (2008), 270–278.
37. [37] Mathur, A., Hernandez, J., Shaheen, F., Shroff, M., Dahal, S., Morton, C., et al. Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma. HPB Oxf 13 (2011), 404–410.
38. [38] Miljkovic, I., Cauley, J.A., Wang, P.Y., Holton, K.F., Lee, C.G., Sheu, Y., et al. Abdominal myosteatosis is independently associated with hyperinsulinemia and insulin resistance among older men without diabetes. Obes (Silver Spring) 21 (2013), 2118–2125.
39. [39] Shaw, C.S., Clark, J., Wagenmakers, A.J., The effect of exercise and nutrition on intramuscular fat metabolism and insulin sensitivity. Annu Rev Nutr 30 (2010), 13–34.
40. [40] Miljkovic, I., Kuipers, A.L., Kammerer, C.M., Wang, X., Bunker, C.H., Patrick, A.L., et al. Markers of inflammation are heritable and associated with subcutaneous and ectopic skeletal muscle adiposity in African ancestry families. Metab Syndr Relat Disord 9 (2011), 319–326.